Literature DB >> 19700746

Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression.

Lyndsey A Emery1, Anusri Tripathi, Chialin King, Maureen Kavanah, Jane Mendez, Michael D Stone, Antonio de las Morenas, Paola Sebastiani, Carol L Rosenberg.   

Abstract

Proliferative breast lesions, such as simple ductal hyperplasia (SH) and atypical ductal hyperplasia (ADH), are candidate precursors to ductal carcinoma in situ (DCIS) and invasive cancer. To better understand the relationship of breast lesions to more advanced disease, we used microdissection and DNA microarrays to profile the gene expression of patient-matched histologically normal (HN), ADH, and DCIS from 12 patients with estrogen receptor positive sporadic breast cancer. SH were profiled from a subset of cases. We found 837 differentially expressed genes between DCIS-HN and 447 between ADH-HN, with >90% of the ADH-HN genes also present among the DCIS-HN genes. Only 61 genes were identified between ADH-DCIS. Expression differences were reproduced in an independent cohort of patient-matched lesions by quantitative real-time PCR. Many breast cancer-related genes and pathways were dysregulated in ADH and maintained in DCIS. Particularly, cell adhesion and extracellular matrix interactions were overrepresented. Focal adhesion was the top pathway in each gene set. We conclude that ADH and DCIS share highly similar gene expression and are distinct from HN. In contrast, SH appear more similar to HN. These data provide genetic evidence that ADH (but not SH) are often precursors to cancer and suggest cancer-related genetic changes, particularly adhesion and extracellular matrix pathways, are dysregulated before invasion and even before malignancy is apparent. These findings could lead to novel risk stratification, prevention, and treatment approaches.

Entities:  

Mesh:

Year:  2009        PMID: 19700746      PMCID: PMC2731147          DOI: 10.2353/ajpath.2009.090115

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays.

Authors:  Chialin King; Ning Guo; Garrett M Frampton; Norman P Gerry; Marc E Lenburg; Carol L Rosenberg
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

2.  An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.

Authors:  S R Wellings; H M Jensen; R G Marcum
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

3.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.

Authors:  P O'Connell; V Pekkel; S A Fuqua; C K Osborne; G M Clark; D C Allred
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

4.  Prognostic classification of breast ductal carcinoma-in-situ.

Authors:  M J Silverstein; D N Poller; J R Waisman; W J Colburn; A Barth; E D Gierson; B Lewinsky; P Gamagami; D J Slamon
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

5.  Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis.

Authors:  Indira Poola; Robert L DeWitty; Josephine J Marshalleck; Rakesh Bhatnagar; Jessy Abraham; LaSalle D Leffall
Journal:  Nat Med       Date:  2005-05-01       Impact factor: 53.440

6.  Evaluation of pathways for progression of heterogeneous breast tumors.

Authors:  Laura Sontag; David E Axelrod
Journal:  J Theor Biol       Date:  2005-01-21       Impact factor: 2.691

7.  Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.

Authors:  R F Chuaqui; Z Zhuang; M R Emmert-Buck; L A Liotta; M J Merino
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

8.  Benign breast disease and the risk of breast cancer.

Authors:  Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Wilma L Lingle; Amy C Degnim; Karthik Ghosh; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; David W Hillman; Vera J Suman; Jo Johnson; Cassann Blake; Thea Tlsty; Celine M Vachon; L Joseph Melton; Daniel W Visscher
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 9.  The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.

Authors:  Jorge S Reis-Filho; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2003-10-09       Impact factor: 6.466

10.  Gene expression profiling of the tumor microenvironment during breast cancer progression.

Authors:  Xiao-Jun Ma; Sonika Dahiya; Elizabeth Richardson; Mark Erlander; Dennis C Sgroi
Journal:  Breast Cancer Res       Date:  2009-02-02       Impact factor: 6.466

View more
  34 in total

Review 1.  Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions.

Authors:  Nathan J Godde; Ryan C Galea; Imogen A Elsum; Patrick O Humbert
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-12       Impact factor: 2.673

2.  Keratin 19 expression correlates with poor prognosis in breast cancer.

Authors:  Nuzhat N Kabir; Lars Rönnstrand; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

3.  PathScan: a tool for discerning mutational significance in groups of putative cancer genes.

Authors:  Michael C Wendl; John W Wallis; Ling Lin; Cyriac Kandoth; Elaine R Mardis; Richard K Wilson; Li Ding
Journal:  Bioinformatics       Date:  2011-04-14       Impact factor: 6.937

4.  Cancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network.

Authors:  Jordi Serra-Musach; Helena Aguilar; Francesco Iorio; Francesc Comellas; Antoni Berenguer; Joan Brunet; Julio Saez-Rodriguez; Miguel Angel Pujana
Journal:  Integr Biol (Camb)       Date:  2012-07-18       Impact factor: 2.192

5.  Microproteomic analysis of 10,000 laser captured microdissected breast tumor cells using short-range sodium dodecyl sulfate-polyacrylamide gel electrophoresis and porous layer open tubular liquid chromatography tandem mass spectrometry.

Authors:  Dipak Thakur; Tomas Rejtar; Dongdong Wang; Jonathan Bones; Sangwon Cha; Buffie Clodfelder-Miller; Elizabeth Richardson; Shemeica Binns; Sonika Dahiya; Dennis Sgroi; Barry L Karger
Journal:  J Chromatogr A       Date:  2011-09-14       Impact factor: 4.759

6.  Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium.

Authors:  Kelly Graham; Xijin Ge; Antonio de Las Morenas; Anusri Tripathi; Carol L Rosenberg
Journal:  Clin Cancer Res       Date:  2010-11-08       Impact factor: 12.531

7.  Identification of breast cancer prognosis markers using integrative sparse boosting.

Authors:  S Ma; J Huang; Y Xie; N Yi
Journal:  Methods Inf Med       Date:  2012-02-20       Impact factor: 2.176

8.  Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds.

Authors:  Naing Lin Shan; Audrey Minden; Philip Furmanski; Min Ji Bak; Li Cai; Roman Wernyj; Davit Sargsyan; David Cheng; Renyi Wu; Hsiao-Chen D Kuo; Shanyi N Li; Mingzhu Fang; Hubert Maehr; Ah-Ng Kong; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-28

9.  Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.

Authors:  Núria Bonifaci; Bohdan Górski; Bartlomiej Masojć; Dominika Wokołorczyk; Anna Jakubowska; Tadeusz Dębniak; Antoni Berenguer; Jordi Serra Musach; Joan Brunet; Joaquín Dopazo; Steven A Narod; Jan Lubiński; Conxi Lázaro; Cezary Cybulski; Miguel Angel Pujana
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

Review 10.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.